Danaher (DHR) Stock Looks Fairly Valued On Cash Flow Yet Overvalued On Earnings
Danaher stock has delivered a decline of about 27.5% over the past five years, yet current valuation checks show a share price that screens as fairly aligned with an intrinsic value estimate from a Discounted Cash Flow (DCF) approach, while traditional market multiples suggest the stock leans expensive.
- Over roughly five years, Danaher has declined 27.5%, which raises questions about whether the current price fairly reflects the company’s prospects and risks.
- New product clearances at Masimo and Danaher’s role in the growing molecular diagnostics market can support long term cash flow expectations. However, any setback in adoption of these technologies may weigh on market confidence in those cash flows.
- On a broad set of valuation checks, including both intrinsic value and market multiples, Danaher scores 2 out of 6, which points to a stock that does not screen as a clear bargain overall.
The issue now is whether Danaher’s current price around its intrinsic value estimate leaves enough margin of safety, given the premium indicated by market multiples.
Scan opportunities beyond Danaher by comparing it with solid balance sheet and fundamentals stocks screener (53 results) that may offer a stronger mix of resilience and valuation support.
Is Danaher Fairly Priced on Cash Flow?
The Discounted Cash Flow model used here projects how much cash Danaher might generate for shareholders and brings those future dollars back to today’s value. Danaher’s latest twelve month free cash flow sits at about $5.3b, with the model assuming that cash flows grow over time rather than shrink, which aligns with a mature but still expanding life sciences business.
Based on these assumptions, the model arrives at an intrinsic value of about $228 per share, which implies the stock screens roughly 9.4% undervalued versus the current price. Because MarketsandMarkets highlights Danaher as a key player in the growing molecular diagnostics market, the cash flow outlook embedded in this DCF may appear reasonable for investors who believe that segment can keep contributing meaningfully.
On balance, this Discounted Cash Flow view suggests Danaher stock screens as roughly fairly valued, with only a modest discount to intrinsic value.
Danaher is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.
Is Danaher Getting Expensive on Earnings?
The P/E ratio is a useful cross check for a company like Danaher because earnings are a key reference point for many investors in established life sciences businesses.
Danaher trades on a P/E of about 36.5x, compared with a Life Sciences industry average of about 37.6x and a peer average of roughly 32.5x. The fair P/E ratio from this model is about 32.0x, which is lower than the current market multiple. That gap suggests investors are paying a higher price for each dollar of Danaher earnings than the model would imply based on its growth profile, margins, size and risk characteristics.
This does not mean the stock cannot deliver acceptable long term outcomes, but it does indicate that on earnings alone Danaher is priced at a premium to what this framework flags as a more grounded level.
On the P/E test, Danaher stock looks overvalued relative to the earnings multiple this model views as reasonable.
See what the numbers say about this price — find out in our valuation breakdown.
The Danaher Narrative: What Would Justify Today's Price?
For Danaher, Simply Wall St Narratives sit between the DCF work and the P/E check you have just seen. They spell out what kind of future for growth, margins and earnings would need to unfold for the stock to be worth meaningfully more or less than today’s price on the Community page. Each one turns Danaher's implied fair value into a specific thesis about the business that you can watch over time, rather than a single static number.
You can be one of the first voices in the Simply Wall St community to set out a clear, number driven narrative on Danaher and share a view on how developments like Masimo’s FDA clearance for its hemodynamic monitoring solution might shape the story from here. Publish your thesis, track it as new results and product updates arrive, and see how Danaher's actual progress lines up with your expectations.
Do you think there's more to the story for Danaher? Head over to our Community to see what others are saying!
The Bottom Line
For Danaher, the Discounted Cash Flow (DCF) work points to a share price that is close to intrinsic value, with only a modest discount. The earnings multiple view is less generous and suggests the stock is overvalued on P/E compared with what its profile would usually justify. That mix, alongside a low overall value score, points to a situation where valuation is not clearly in your favor. The central question from here is whether Danaher can deliver the cash flow and earnings progress needed to support a premium multiple without leaving you overpaying for that quality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com